21 registrations that name mazdutide as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Trial FinderInvestigational, not FDA-approvedRead from ClinicalTrials.gov Oct 20, 2026The Mazdutide peptide page
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 21 registrations
Status
Phase
50US sites across 22 states
1
2 to 4
5 to 19
20 or more
All 21 registrations
RecruitingNCT06143956
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
Phase 2
Eli Lilly and Company
About 1,481 people
Started Nov 17, 2023
In plain words A Phase 2 study of mazdutide in people 18 to 75, run by Eli Lilly and Company. It plans to enroll about 1,481 people at 57 sites, 50 of them in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 75. Conditions: Obesity; Overweight.
Have a body mass index (BMI)
≥30 kilogram/square meter (kg/m²), or
≥27 kg/m² and <30 kg/m², or with at least 1 weight-related comorbidity
Have had a stable body weight for the 3 months prior to randomization (<5%) body weight gain and/or loss.
The purpose of this Phase-2 chronic weight management master protocol (CWMM) is to create a framework to evaluate the safety and efficacy of various investigational interventions for chronic weight management with intervention-specific appendices (ISAs). The CWMM establishes entry criteria for newly enrolled participants across the master and the ISAs. The ISAs may start independently of other ISAs as interventions become available for clinical testing. The results for the CWMM screening record will be reported when all the ISA's complete.
Where, as registered
50 US sites in 22 states; also Argentina (7).
RecruitingNCT07083154
Mazdutide in Type 2 Diabetes With Early-Stage Cognitive Impairment (LIGHT-COG Study)
Phase 3
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
About 420 people
Started Sep 27, 2025
In plain words A Phase 3 study of mazdutide in people 50 to 75, run by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School. It plans to enroll about 420 people at 8 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 50 to 75. Conditions: Dementia, Mild; Mild Cognitive Impairment; Type 2 Diabetes.
Diagnosis of type 2 diabetes according to the American Diabetes Association criteria;
Aged 50-75 years (inclusive), male or female.
Early-stage cognitive impairment (defined as mild cognitive impairment or mild dementia), with all of the following:
MMSE score >20 and <27,
13 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Mazdutide; Placebo
Registered summary
The LIGHT-COG study is a 76-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group clinical trial evaluating the efficacy and safety of mazdutide in 420 participants with type 2 diabetes (T2D) and early-stage cognitive impairment, defined as mild cognitive impairment (MCI) or mild dementia. Participants are randomized 1:1 to receive once-weekly subcutaneous mazdutide, with dose escalation according to the protocol, or matching placebo, in addition to background glucose-lowering therapy. The full summary is on the listing.
Where, as registered
No US site; China (8).
RecruitingNCT07517042
ASCEND-1: Lifestyle Intervention Plus Mazdutide for Weight Management
No phase
Shanghai Zhongshan Hospital
About 420 people
Started Jun 10, 2026
In plain words A study of mazdutide in people 18 and older, run by Shanghai Zhongshan Hospital. It plans to enroll about 420 people at 13 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Obesity; Weight Control.
Adult men or women aged 18 years or older;
Simple obesity, defined as a body mass index (BMI) of 28.0-45.0 kg/m²;
Able and willing to provide written informed consent.
The exclusion criteria are on the listing.
What it tests, as registered
Mazdutide; Intensive Lifestyle Intervention
Registered summary
Obesity is a chronic, progressive, and relapsing disease. Although lifestyle interventions and anti-obesity medications are effective for inducing weight loss, evidence regarding their role in long-term weight maintenance after pharmacologically induced weight reduction remains limited. In addition, the high cost and potential adverse effects of weight-loss medications restrict their prolonged use, and it is unclear whether low dose medication, intensive life style intervention or together can serve as an effective strategy for weight maintenance. The full summary is on the listing.
Where, as registered
No US site; China (13).
RecruitingNCT07469800
Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/Obesity
Phase 3
Innovent Biologics (Suzhou) Co. Ltd.
About 336 people
Started Apr 23, 2026
In plain words A Phase 3 study of mazdutide in people 18 and older, run by Innovent Biologics (Suzhou) Co. Ltd.. It plans to enroll about 336 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Overweight; Obesity; Hypertensive.
Aged ≥ 18 years old at the time of signing the informed consent form.
Confirmed diagnosis of hypertension.
No prior history of antihypertensive medication treatment at screening; or previously received only one type of antihypertensive medication during the same period and has discontinued all antihypertensive medications for at least 2 weeks…
Voluntarily sign the informed consent form and be willing to strictly comply with the requirements and restrictions stated in the informed consent form and the protocol throughout the study, including but not limited to: maintaining a…
The exclusion criteria are on the listing.
What it tests, as registered
IBI362; Placebo
Registered summary
A multicenter, randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of IBI362 in participants with mild to moderate hypertension complicated by overweight/obesity who have not received antihypertensive drug treatment
Where, as registered
No US site; China (1).
RecruitingNCT06931028
A Study of IBI362 in Chinese Subjects With Obstructive Sleep Apnea and BMI≥28 kg/m2
Phase 3
Innovent Biologics (Suzhou) Co. Ltd.
About 260 people
Started Jun 12, 2025
In plain words A Phase 3 study of mazdutide in people 18 and older, run by Innovent Biologics (Suzhou) Co. Ltd.. It plans to enroll about 260 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Sleep Apnea; Obstructive; Obesity.
For PAP s: Subjects who have received positive airway pressure (PAP) therapy for at least 3 consecutive months prior to screening and plan to continue PAP therapy during the study.
For non-PAP s:Subjects who are unable or unwilling to undergo PAP therapy. PAP must not have been used for at least 4 weeks prior to screening.
For all subjects:
Age ≥18 years at the time of signing informed consent.
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
placebo; IBI362
Registered summary
This is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study to evaluate the efficacy and safety of IBI362 in subjects with moderate-to-severe obstructive sleep apnea (OSA) and a body mass index (BMI) ≥28 kg/m2. Subjects will be randomly assigned to IBI362 9 mg and placebo groups. All study treatment will be administered once-weekly and subcutaneously. The entire trial cycle includes a 4-week screening period, a 48-week double-blind treatment period, and a 12-week drug withdrawal follow-up period after the end of treatment.
Where, as registered
No US site; China (1).
RecruitingNCT07633639
GLP-1 Therapy After Bariatric Surgery in Chinese Patients With Obesity
No phase
China-Japan Friendship Hospital
About 200 people
Started May 1, 2026
In plain words A study of mazdutide in people 18 to 60, run by China-Japan Friendship Hospital. It plans to enroll about 200 people at 1 site, none in the US.
Metabolic comorbidities: Diagnosis of metabolic syndrome or type 2 diabetes mellitus (T2DM) meeting standard criteria.
Age range: 18-60 years (inclusive).
1 more inclusion criterion and the exclusion criteria are on the listing.
What it tests, as registered
LSG-Semaglutide group; LSG-Mazdutide group; LSG-Tirzepatide group; LSG group
Registered summary
Obese patients exhibit considerable heterogeneity and complex comorbidities, making long-term effective management challenging with monotherapy. While bariatric surgery remains the most effective weight-loss intervention, postoperative weight regain and metabolic deterioration remain significant concerns. glucagon-like peptide-1 receptor agonists (GLP-1RA) offer distinct advantages for weight loss and metabolic control, and their combination with surgery may produce synergistic effects. The full summary is on the listing.
Where, as registered
No US site; China (1).
RecruitingNCT07255209
A Study of IBI362 in Chinese Adolescents With Obesity or Overweight
Phase 3
Innovent Biologics (Suzhou) Co. Ltd.
About 180 people
Started Dec 29, 2025
In plain words A Phase 3 study of mazdutide in people 12 to 18, run by Innovent Biologics (Suzhou) Co. Ltd.. It plans to enroll about 180 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 12 to 18. Conditions: Adolescents With Obesity or Overweight With Weight-Related Comorbidities.
Male or female participants aged ≥12 years and <18 years at the time of signing the informed consent/assent form.
BMI at screening meeting the obesity criteria defined by "WS/T 586-2018 Screening for Overweight and Obesity in School-Age Children and Adolescents" or meeting overweight criteria plus at least one weight-related comorbidity: prediabetes,…
Weight change <5 kg after ≥12 weeks of diet and exercise alone before screening (per self/parental report).
The exclusion criteria are on the listing.
What it tests, as registered
Placebo; IBI362
Registered summary
The study is designed to assess the efficacy and safety of multiple doses of IBI362 in Chinese adolescent subjects with obesity or overweight. It plans to enroll 180 adolescents (aged ≥12 and \<18 years) who have failed to achieve a 5 kg weight reduction after at least 12 weeks of dietary and exercise intervention.
Where, as registered
No US site; China (1).
RecruitingNCT06937749
A Study of IBI362 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Phase 2
Innovent Biologics (Suzhou) Co. Ltd.
About 165 people
Started Jul 1, 2025
In plain words A Phase 2 study of mazdutide in people 18 and older, run by Innovent Biologics (Suzhou) Co. Ltd.. It plans to enroll about 165 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Metabolic Dysfunction-associated Steatohepatitis (MASH).
Must be willing to participate in the study and provide written informed consent.
Male or female, age 18 years or older at the time of signing informed consent
Body mass Index (BMI) ≥25 kg/m²
Diagnosis of Metabolic dysfunction-associated steatohepatitis (MASH) (Non-alcoholic Fatty Liver Disease (NAFLD) Activity Score (NAS) ≥ 4, with at least 1 point in steatosis, inflammation and ballooning each) and fibrosis stage F2 or F3…
The exclusion criteria are on the listing.
What it tests, as registered
Placebo; IBI362
Registered summary
This is a multicenter, randomized, double-blind, placebo-controlled Phase 2 clinical study evaluating the efficacy and safety of IBI362 in MASH subjects. Subjects will be randomly assigned to IBI362 low-dose, high-dose and placebo groups. The entire trial cycle includes a 8-week screening period, a 60-week double-blind treatment period, and a 4-week follow-up period.
Where, as registered
No US site; China (1).
RecruitingNCT07657676
Effect of Mazdutide on Coronary Plaque in Patients With Coronary Atherosclerosis and Overweight or Obesity
Phase 4
China National Center for Cardiovascular Diseases
About 116 people
Started Sep 14, 2026
In plain words A Phase 4 study of mazdutide in people 18 and older, run by China National Center for Cardiovascular Diseases. It plans to enroll about 116 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Obesity & Overweight; Coronary Heart Disease.
Age ≥ 18 years
BMI ≥ 28 kg/m2 or BMI≥ 24kg/m2 with at least one of the following conditions: dyslipidemia, metabolic associated fatty liver disease, hypertension, prediabetes, type 2 diabetes mellitus, or obesity-related obstructive sleep apnea syndrome…
Coronary stenosis 30-70% confirmed by CAG or CCTA within 3 months prior to enrollment.
Signed informed consent
1 more inclusion criterion and the exclusion criteria are on the listing.
What it tests, as registered
Mazdutide; Placebo
Registered summary
This multicenter, randomized, double-blind, placebo-controlled trial aims to evaluate the effect of mazdutide, a dual GLP-1/GCG receptor agonist, on coronary plaque progression assessed by coronary computed tomography angiography (CCTA) in patients with coronary atherosclerosis and overweight or obesity. The primary endpoint is the change in total non-calcified plaque volume (NCPV) from baseline to week 52. The full summary is on the listing.
Where, as registered
No US site; China (1).
RecruitingNCT07718126
Pre-hepatectomy Rehabilitation in Obese MASLD-Complicated Living Liver Donors With Mazdutide (PRIME)
Phase 4
West China Hospital
About 60 people
Started Sep 1, 2026
In plain words A Phase 4 study of mazdutide in people 18 to 60, run by West China Hospital. It plans to enroll about 60 people at 4 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 60. Conditions: Metabolic Dysfunction-Associated Steatohepatitis; Hepatic Steatosis; Living Liver Donors.
Age between 18 and 60 years old at the time of signing the informed consent form.
Overweight, defined as Body Mass Index (BMI) ≥ 24 kg/m².
Diagnosed with MASLD by non-invasive means (conventional ultrasound, FibroScan®, or MRI), with a Controlled Attenuation Parameter (CAP) ≥ 268 dB/m via FibroScan®.
Histologically confirmed MASLD without any liver fibrosis, presenting a NAS ≥ 3, including a steatosis subscore ≥ 2 (subscores for hepatocyte ballooning and lobular inflammation are not limited).
2 more inclusion criteria and the exclusion criteria are on the listing.
The purpose of this study is to evaluate the efficacy and safety of a short-term (12-week) prehabilitation strategy combining mazdutide (a novel GLP-1/GCG receptor dual agonist) with lifestyle optimization, compared to lifestyle optimization alone, in potential living liver transplantation donors with metabolic dysfunction-associated steatohepatitis (MASLD). Overweight or obese individuals who intend to donate a portion of their liver but are temporarily disqualified due to hepatic steatosis will be recruited across multiple clinical centers. The full summary is on the listing.
Where, as registered
No US site; China (4).
Not yet recruitingNCT07417306
A Study of HDM1005 in Participants With T2DM Not Controlled With Metformin Alone or in Combination With a Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor
In plain words A Phase 3 study of mazdutide in people 18 to 75, run by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.. It plans to enroll about 912 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 75. Conditions: Type 2 Diabetes.
Confirmed as Type 2 Diabetes Mellitus (T2DM) for at least 12 weeks and on a stable dosage of metformin alone or in combination with an SGLT2 inhibitor for at least 12 weeks prior to screening.
Hemoglobin A1c (HbA1c) ≥7.5% and ≤11.0% (local laboratory) at screening; and ≥7.0% and ≤11.0% (central laboratory) at randomization.
Body Mass Index (BMI) ≥22.5 kg/m2.
The exclusion criteria are on the listing.
What it tests, as registered
HDM1005 1; HDM1005 2; Mazdutide
Registered summary
This study is a multicenter, randomized, open-label, parallel-group, phase 3 clinical trial aimed at evaluating the efficacy and safety of HDM1005 versus active comparator in subjects with Type 2 Diabetes Mellitus (T2DM) Inadequate Glycemic Control by Metformin Monotherapy or in Combination With a Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor. A total of 912 subjects will be enrolled. The full summary is on the listing.
Where, as registered
No US site; China (1).
Not yet recruitingNCT07775846
QUARTET-DKD: Quadruple Therapy for Type 2 Diabetic Nephropathy
Phase 4
Huijie Zhang
About 820 people
Starts Sep 1, 2026 (estimated)
In plain words A Phase 4 study of mazdutide in people 18 to 70, run by Huijie Zhang. It plans to enroll about 820 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 70. Conditions: Type 2 Diabetic Kidney Disease.
Age ≥18 years, with a confirmed diagnosis of type 2 diabetes mellitus (T2DM).
Receiving a standard dose of an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) therapy for at least 4 consecutive weeks prior to screening, with the dose expected to remain stable throughout the study…
Body Mass Index (BMI) ≥ 24.0 kg/m2.
Mean urine albumin-to-creatinine ratio (UACR) ≥ 100 mg/g and < 5000 mg/g, calculated from first morning void urine samples collected over 3 consecutive days.
4 more inclusion criteria and the exclusion criteria are on the listing.
This study employs a prospective, randomized, double-blind, parallel-controlled design, aiming to enroll adult participants with type 2 diabetic kidney disease (DKD) who meet the eligibility criteria. With an angiotensin receptor blocker (ARB) as the background therapy, all participants will be randomized in a 1:1:1:1 ratio into four treatment groups: Group 1 (G1): ARB + empagliflozin + finerenone placebo + mazdutide placebo; Group 2 (G2): ARB + empagliflozin + finerenone + mazdutide placebo; Group 3 (G3): ARB + empagliflozin + mazdutide + finerenone placebo; Group 4 (G4): ARB + empagliflozin… The full summary is on the listing.
Where, as registered
No US site; China (1).
Not yet recruitingNCT07135141
Mazdutide as Adjuvant Therapy Following Sleeve Gastrectomy in Severe Obesity
No phase
Beijing Friendship Hospital
About 256 people
Starts Sep 30, 2025 (estimated)
In plain words A study of mazdutide in people 18 to 70, run by Beijing Friendship Hospital. It plans to enroll about 256 people at 14 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 70. Conditions: Severe Obesity.
Aged 18-70 years (inclusive), male or female;
BMI≥37.5 kg/m2, with or without obesity-related complications;
Planned to take sleeve gastrectomy
Understand the trial protocol, voluntarily sign the informed consent form (ICF), and agree to follow all study requirements and restrictions.
The exclusion criteria are on the listing.
What it tests, as registered
Sleeve gastrectomy plus early mazdutide initiation; Sleeve gastrectomy followed with early mazdutide placebo initation
Registered summary
The SMART study is a 96-week, multicenter, randomized, double-blind, placebo-controlled superiority clinical trial. A total of 256 severe obesity patients are randomized 1:1 to either receive the bariatric surgery plus GCG/GLP-1 dual receptor agonist group (receiving sleeve gastrectomy followed by subcutaneous injections of mazdutide weekly, with stepwise dose escalation to a maintenance dose per protocol) or the bariatric surgery plus placebo group (receiving matched procedure plus placebo injections). The full summary is on the listing.
Where, as registered
No US site; China (14).
Not yet recruitingNCT07767552
Mazdutide for Remission of Type 2 Diabetes: Multicentre, Double Blind, Randomised, Placebo Controlled Trial
No phase
Yanbing Li
About 249 people
Starts Sep 30, 2026 (estimated)
In plain words A study of mazdutide in people 18 to 70, run by Yanbing Li. It plans to enroll about 249 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 70. Conditions: Diabetes Mellitus, Type 2.
What it tests, as registered
Mazdutide; Placebo
Registered summary
The purpose of this study is to investigate and efficacy of Mastitide for diabetes remission in Chinese type 2 diabetic subjects with poor glycemic control on diet or exercise therapy alone or metformin/sodium-glucose cotransporter (SGLT2) inhibitor monotherapy.
Where, as registered
No US site; China (1).
Not yet recruitingNCT07843862
A Study of HRS-4729 Injection in Participants With Type 2 Diabetes
Phase 2
Fujian Shengdi Pharmaceutical Co., Ltd.
About 240 people
Starts Oct 2026 (estimated)
In plain words A Phase 2 study of mazdutide in people 18 to 65, run by Fujian Shengdi Pharmaceutical Co., Ltd.. It plans to enroll about 240 people at 2 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 65. Conditions: Type 2 Diabetes.
Have Type 2 Diabetes
Treated with diet and exercise alone or with a stable dose of metformin
Have an HbA1c value at screening of ≥7.5% and ≤10.5%
The exclusion criteria are on the listing.
What it tests, as registered
HRS-4729 Injection; Mazdutide; Placebo
Registered summary
The main purpose of this study is to evaluate the efficacy and safety of HRS-4729 Injection in participants with type 2 diabetes who failed to achieve adequate glycemic control on diet and exercise alone or on a stable dose of metformin.
Where, as registered
No US site; China (2).
Not yet recruitingNCT07803705
Efficacy of Mazdutide on Fatty Pancreas
No phase
Tongji Hospital
About 194 people
Starts Nov 15, 2026 (estimated)
In plain words A study of mazdutide in people 18 to 60, run by Tongji Hospital. It plans to enroll about 194 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 60. Conditions: Fatty Pancreas; Overweight; Obesity.
Age 18-60 years (inclusive) at screening, regardless of gender;
BMI at screening meets one of the following conditions: ① BMI ≥28 kg/m²; or ② 24 kg/m² ≤ BMI <28 kg/m², with at least one obesity-related metabolic abnormality (elevated fasting blood glucose, dyslipidemia, hypertension, etc.);
Pancreatic MRI-PDFF quantitative assessment completed during the screening period, with intrapancreatic fat deposition (IPFD) ≥6%;
Fully informed about the study and voluntarily signed written informed consent;
6 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
mazdutide; Placebo matching mazdutide
Registered summary
This is a randomized, double-blind, placebo-controlled, parallel-group, single-center clinical trial designed to evaluate the efficacy and safety of mazdutide in improving fatty pancreas in patients with overweight or obesity. The study plans to enroll 194 participants with overweight or obesity, who will be randomly assigned in a 1:1 ratio to either the mazdutide plus standardized lifestyle intervention group or the placebo plus standardized lifestyle intervention group, for a treatment duration of 48 weeks. The full summary is on the listing.
Where, as registered
No US site; China (1).
Not yet recruitingNCT07654062
Mazdutide for Adults With Prediabetes: A Randomized, Double-Blind, Placebo-Controlled Trial (DREAM-PRE)
Phase 4
Shandong Provincial Hospital
About 150 people
Starts Jul 2026 (estimated)
In plain words A Phase 4 study of mazdutide in people 18 to 75, run by Shandong Provincial Hospital. It plans to enroll about 150 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 75. Conditions: Prediabetes; Impaired Fasting Glucose; Impaired Glucose Tolerance (Prediabetes).
Voluntarily signed written informed consent prior to any study procedures
Age 18 to 75 years (inclusive) at the time of signing informed consent; male or female
Prediabetes confirmed by central laboratory at screening, meeting at least one of the following criteria per Chinese Diabetes Society (CDS) standards, and not meeting diagnostic criteria for diabetes:
Prediabetes affects millions of adults worldwide and carries a high risk of progression to type 2 diabetes. Mazdutide is a once-weekly injectable drug that activates both GLP-1 and glucagon receptors, lowering blood sugar and body weight simultaneously. This study (DREAM-PRE) tests whether mazdutide can help adults with prediabetes return to normal blood sugar levels. Approximately 150 adults aged 18-75 years with prediabetes and BMI ≥22 kg/m² will be randomly assigned in equal numbers to one of three groups: mazdutide 4 mg once weekly, mazdutide 6 mg once weekly, or placebo once weekly. The full summary is on the listing.
Where, as registered
No US site; China (1).
Not yet recruitingNCT07781150
Mazdutide Plus LNG-IUS for Fertility-Sparing Treatment of AEH or Early Endometrial Cancer
Phase 2
Tongji Hospital
About 128 people
Starts Nov 1, 2026 (estimated)
In plain words A Phase 2 study of mazdutide in female participants 18 to 45, run by Tongji Hospital. It plans to enroll about 128 people at 6 sites, none in the US.
Participants have a clear desire to preserve fertility, fully understand that fertility-sparing treatment is not the standard radical treatment for endometrial cancer, are willing to accept the potential risks of disease progression or…
Histologically confirmed disease meeting one of the following criteria: atypical endometrial hyperplasia; or FIGO grade 1 endometrioid endometrial cancer meeting FIGO 2023 stage IA1, with disease confined to the endometrium or an…
Imaging confirms disease confined to the endometrium, with no evidence of myometrial invasion, adnexal involvement, extrauterine disease, or distant metastasis.
9 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Mazdutide(Dual GLP-1R/GCGR Agonist); Placebo; Levonorgestrel-releasing intrauterine system
Registered summary
This is a prospective, multicenter, randomized, double-blind, placebo-controlled, parallel-group clinical trial designed to evaluate the efficacy and safety of mazdutide combined with a levonorgestrel-releasing intrauterine system (LNG-IUS) for fertility-sparing treatment in overweight or obese patients with atypical endometrial hyperplasia (AEH) or early-stage endometrioid endometrial cancer. Eligible participants will be randomized in a 1:1 ratio to receive LNG-IUS plus mazdutide or LNG-IUS plus matching placebo. The full summary is on the listing.
Where, as registered
No US site; China (6).
Not yet recruitingNCT07713992
Efficacy and Safety of Mazdutide in Patients With Type 2 Diabetes Mellitus and Moderate to Severe Nonalcoholic Fatty Liver Disease Previously Treated With Semaglutide
No phase
Tianjin Medical University
About 72 people
Starts Sep 15, 2026 (estimated)
In plain words A study of mazdutide in people 18 to 60, run by Tianjin Medical University. It plans to enroll about 72 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 60. Conditions: Type 2 Diabetes Mellitus (T2DM); Nonalcoholic Fatty Liver Disease (NAFLD) With History of Diabetes Melitus.
Aged between 18 and 60 years (inclusive) at the time of informed consent signing.
Diagnosed with type 2 diabetes mellitus.
Received once-weekly semaglutide 1.0 mg treatment for at least 16 consecutive weeks verified by medication records.
Diagnosed with moderate-to-severe fatty liver, defined as hepatic attenuation ≥269 dB/m by transient elastography and hepatic fat fraction >10% measured by MRI-PDFF.
4 more inclusion criteria and the exclusion criteria are on the listing.
This is a multicenter, prospective, randomized controlled investigator-initiated trial (IIT) aimed at evaluating the efficacy and safety of switching to mazdutide therapy in patients with type 2 diabetes mellitus (T2DM) and moderate-to-severe non-alcoholic fatty liver disease (NAFLD) who have achieved glycemic control. Chinese patients with type 2 diabetes mellitus (T2DM) are susceptible to visceral fat accumulation, which increases the risk of cardiometabolic diseases and mortality. The full summary is on the listing.
Where, as registered
No sites listed yet.
Not yet recruitingNCT07797101
Body-weight Reduction Effect on Portal Hypertension in Compensated Cirrhosis
No phase
The Second Affiliated Hospital of Chongqing Medical University
About 50 people
Starts Sep 1, 2026 (estimated)
In plain words A study of mazdutide in people 18 to 75, run by The Second Affiliated Hospital of Chongqing Medical University. It plans to enroll about 50 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 75. Conditions: Cirrhosis; Portal Hypertension; Fatty Liver Disease; GLP-1.
Aged 18 to 75 years (inclusive), male or female.
Documented etiology of chronic liver disease, limited to chronic hepatitis B, chronic hepatitis C, metabolic dysfunction-associated steatotic liver disease (MASLD), or alcohol-related liver disease.
Cirrhosis confirmed by imaging (ultrasound, CT, or MRI), or pathology showing F3/F4 fibrosis, or liver stiffness measurement (LSM) ≥15 kPa by vibration-controlled transient elastography (VCTE).
Hepatic venous pressure gradient (HVPG) ≥10 mmHg.
4 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Mazdutide injection
Registered summary
Obesity and metabolic abnormalities accelerate decompensation in compensated cirrhosis, driven by clinically significant portal hypertension (CSPH, HVPG≥10 mmHg). Lifestyle-induced weight loss can lower portal pressure, but pharmacological options are limited. Mazdutide, a dual GLP-1/glucagon receptor agonist, has proven weight-loss and glycaemic benefits, yet its safety and efficacy in cirrhosis with portal hypertension are unknown. The full summary is on the listing.
Where, as registered
No sites listed yet.
Not yet recruitingNCT07824895
Mazdutide for Weight Management and Gout in Adults With Obesity
Phase 4
Hongwei Jiang
About 30 people
Starts Sep 15, 2026 (estimated)
In plain words A Phase 4 study of mazdutide in people 18 to 65, run by Hongwei Jiang. It plans to enroll about 30 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 65. Conditions: Gout; Obesity (BMI>30); Hyperuricemia; Metabolic Syndrome.
Informed consent is obtained before trial entry, and the subject fully understands the trial content, procedures, and potential adverse reactions; able to complete the study according to the protocol requirements.
Subjects (including male subjects) have no plans for pregnancy, sperm donation, or egg donation from 14 days before screening until 3 months after trial completion, and voluntarily agree to use effective contraception.
Aged 18 to 65 years (inclusive), male or female.
Obesity: BMI ≥ 30.0 kg/m².
5 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Mazdutide
Registered summary
This is a single-arm, open-label, pre-post controlled study to evaluate the effect of Mazdutide on the annualized flare rate (AFR) in adults with obesity and gout. The study will enroll 30 subjects aged 18 to 65 years with a Body Mass Index (BMI) ≥ 30.0 kg/m². Eligible participants must have a confirmed diagnosis of gout and a history of at least 2 gout flares in the past 6 months. The primary objective is to compare the AFR during the 52-week treatment period with the 12 months prior to treatment. The full summary is on the listing.